How long does it take to take Alpelisib to develop drug resistance?

Alpelisib (Alpelisib)-Piqray, is an oral PI3Kα selective inhibitor specifically used for patients with HR+/HER2- advanced breast cancer carrying PIK3CA mutations. The mechanism is to selectively inhibit the PI3Kα signaling pathway, thereby interfering with tumor cell proliferation and survival and delaying disease progression. However, similar to other targeted drugs, resistance to apelvis may still develop with long-term use. The drug resistance mechanism is complex and may include activation of alternative signaling pathways by tumor cells, mutational changes in PI3K gene subtypes, and adaptive regulation of the tumor microenvironment. These factors will weaken the efficacy of the drug.

In clinical practice, the time to emergence of resistance varies among individual patients. Some patients may experience a decline in efficacy over several months, while some may maintain a stable response for a longer period of time. Drug resistance is usually manifested by increased tumor markers, imaging examinations showing tumor enlargement or the emergence of new lesions, and patient symptoms may also worsen. In order to delay drug resistance, doctors usually recommend the use of Apelvis in combination with endocrine therapy, such as exemestane, to enhance the efficacy and prolong the treatment response period by dually blocking tumor growth signals.

When resistance occurs, a variety of strategies can be adopted, including adjusting the dose, temporarily discontinuing the drug for observation, or changing the treatment regimen. Research in recent years has also explored ways to overcome resistance by combining other targeted drugs, immunotherapy or PARP inhibitors, thereby extending the treatment window and improving survival prognosis.

Patients should undergo regular imaging and hematology monitoring during medication, and report symptom changes to their doctors in a timely manner so that individualized plans can be formulated. Scientific management and timely intervention can not only delay drug resistance, but also maintain the continuity of treatment, maximize control of disease progression, improve patients' quality of life, and achieve the best results of treatment.

Reference materials:https://www.piqray.com/